Pharmaceutical

Five things for pharma marketers to know: Friday, December 19

Five things for pharma marketers to know: Friday, December 19

By

Roche strikes out in cancer, Alzheimer's trials; Lilly in pact for fast-acting insulin; Humana revamps formulary.

Pfizer bets on Duchenne MD treatment

Pfizer bets on Duchenne MD treatment

By

The company moves on three leading contenders in the muscular dystrophy segment with the start of a Phase II trial

Apotex challenges Amgen blockbuster Neulasta

Canadian firm presents FDA with its third biosimilar application.

Merck buys Swiss biotech

The drugmaker announced it will acquire OncoEthix and its oncology candidate OTX015 in a deal worth up to $365 million

Five things for pharma marketers to know: Thursday, December 18

Five things for pharma marketers to know: Thursday, December 18

By

Shire may bid on NPS Pharmaceuticals; Amgen says cancer drug will cost $178,000; Takeda has a new head of R&D.

Pfizer urges parents to take the pledge against meningitis

Pfizer urges parents to take the pledge against meningitis

By

Pfizer has kicked off a disease-awareness campaign, "Take Action Against Meningitis," urging parents to discuss vaccinations with their healthcare providers with paralympic snowboarder Amy Purdy.

Latest orphan-drug approval marks 15th this year

Latest orphan-drug approval marks 15th this year

By

Swiss drugmaker Novartis received an FDA nod for rare disease treatment Signifor LAR Tuesday, as orphan drug approvals reach new heights.

Pfizer brings humor to menopause marketing

Pfizer brings humor to menopause marketing

The new approach shows "The Talk" has a sequel.

Five things for pharma marketers to know: Tuesday, December 16

Five things for pharma marketers to know: Tuesday, December 16

By By

Bayer consolidates OTC creative portfolio; Genentech R&D head steps down; Novartis receives approval for orphan drug.

FDA 2014 approvals outpace those of 2013

FDA 2014 approvals outpace those of 2013

By

The regulator noted in its early 2014 retrospective that it set a high mark for the number of approved rare disease drugs this year, and that insufficient information is the reason many breakthrough status requests get bounced.

Five things for pharma marketers to know: Friday, December 12

Five things for pharma marketers to know: Friday, December 12

By

Judge rules Actavis must keep Alzheimer's drug on the market; Wyeth CEO joins Roche board, dispelling rumors he may be next Sanofi CEO; Two senators propose new FDA designation which would award 15 years of marketing exclusivity.

Antibiotics maker faces hurdles in diversifying beyond flagship drug

Antibiotics maker faces hurdles in diversifying beyond flagship drug

By

Cubist is re-launching its C.-Diff. antibiotic in an effort to jumpstart sales beyond Cubicin, which contributes most of its product revenue.

Sanofi looks to join M&A trend

Interim CEO Serge Weinberg tells a German paper that the company is prepared to buy assets that meet its goal of providing stable, steady growth.

Pfizer's Lyrica ineffective at treating chronic back pain: study

Researchers found no difference between Lyrica (pregabalin) and placebo in treating lumbar spinal stenosis.

Merck rolls out new Keytruda data in hard-to-treat group

Merck rolls out new Keytruda data in hard-to-treat group

By

The drugmaker shared early-trial results for its PD-1 among hard-to-tread triple-negative breast cancer patients and announced an effort to see if the drug can help patients overcome treatment resistance.

Pfizer's Celebrex slammed by entry of generics

Mylan, Teva, and Actavis announced generics of the $3 billion arthritis drug.

Five things for pharma marketers to know: Wednesday, December 10

Five things for pharma marketers to know: Wednesday, December 10

By

Cubist's best-selling product has four of its five patents invalidated; the first biologic of AbbVie's Humira launches in India; Mylan debuts generic Celebrex.

Lilly psoriasis drug hits Phase-III endpoint

An investigational JAK inhibitor, baricitinib, bested placebo in moderate to severe plaque psoriasis in a Phase-III trial.

Five things for pharma marketers to know: Monday, December 8

Five things for pharma marketers to know: Monday, December 8

By

Merck buys up Cubist in an $8.4B deal, a jury sides with AstraZeneca in a generic Nexium lawsuit and the NYT finds a correlation between Genentech payments and Lucentis prescriptions.

Five things for pharma marketers to know: Friday, December 5

Five things for pharma marketers to know: Friday, December 5

By

GSK opts to hold onto $1.6 billion portfolio of older drugs; Sanofi upheavals continue with exit of US diabetes sales exec; Takeda gains breakthrough status on AL amyloidosis therapy.

Array gets binimetinib all to itself

Transfer of rights to the experimental cancer drug hinges on completion of Novartis/GSK asset swap.

Incyte drug gains expanded indication for bone marrow disease

Jakafi becomes the first drug approved for treating polycythemia vera.

GSK shrinks, and respiratory looks set to stumble

GSK shrinks, and respiratory looks set to stumble

By

Doctors tell investment firm Leerink they don't anticipate upping their prescriptions of the new Ellipta line.

Five for things pharma marketers to know: Thursday, December 4

Five for things pharma marketers to know: Thursday, December 4

By By

Despite drugmaker discount, VA still can't afford Sovaldi without additional funds; Ousted Sanofi CEO Viehbacher faces lawsuit for an alleged kickback scheme; GSK slims sales and R&D workforce.

Trial recruiting looks to tap online community leaders

Trial recruiting looks to tap online community leaders

By

CureClick, TrialReach and WEGO team to leverage health communities and speed trial recruitment.

Lilly nabs rights for osteoporosis patch

The drugmaker inked a deal with Zosano worth up to $440 million for the product, which is about to enter Phase-III in clinical trials.

FDA approves Amgen leukemia immunotherapy

Amgen's Blincyto was approved for a rare form of leukemia after receiving Breakthrough Therapy designation and a Priority Review.

Five things for pharma marketers to know: Wednesday, December 3

Five things for pharma marketers to know: Wednesday, December 3

By By

An Italian court backs the anti-trust's stand that Novartis and Roche colluded in Lucentis marketing; AstraZeneca is the test case for the court's new interpretation of pay-for-delay; early-stage results prompt Biogen Idec to take its experimental Alzheimer's treatment to Phase-III.

High deductibles, costs keep patients away

High deductibles, costs keep patients away

By

More cost data for the file the latest data shows that up-front healthcare costs are prompting many patients to delay office visits.

Actavis launches generic of Intuniv

The first low-cost version of the Shire ADHD drug benefits as a first-filer.


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.

Email Newsletters